Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.44 |
| ▸ | FNTA | P49354 | 3/20 | 0.44 |
| ▸ | FNTB | P49356 | 3/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930049 | 1.00 | NOD1 (0.51) | NOD1GNPATFOLH1FNTAFNTB | |
| SCHEMBL28735998 | 0.89 | GNPAT (0.54) | NOD1GNPATFOLH1FNTAFNTB | |
| SCHEMBL29767070 | 0.89 | GNPAT (0.54) | NOD1GNPATFOLH1FNTAFNTB | |
| SCHEMBL928640 | 0.88 | GNPAT (0.47) | NOD1GNPATFOLH1FNTAFNTB | |
| SCHEMBL4649464 | 0.87 | SLC6A5 (0.51) | NOD1GNPATFOLH1FNTAFNTB | |
| SCHEMBL4649465 | 0.87 | SLC6A5 (0.51) | NOD1GNPATFOLH1FNTAFNTB | |
| SCHEMBL929531 | 0.86 | KDM4E (0.53) | NOD1GNPATFOLH1FNTAFNTB | |
| SCHEMBL20553085 | 0.86 | NOD1 (0.71) | NOD1SLC6A5EPHX2 | |
| SCHEMBL8964448 | 0.86 | NOD1 (0.71) | NOD1SLC6A5EPHX2 | |
| SCHEMBL9752285 | 0.85 | GNPAT (0.62) | NOD1GNPATFOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | claimed |
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | NOD1 4684/4885GNPAT 3899/4885FOLH1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.